ImmunityBio (NASDAQ: IBRX) unveiled a new international partnership designed to expand global access to its cancer therapy, Anktiva.
Specifically, the company announced it has partnered with Accord Healthcare to distribute the treatment across 30 countries. Investors reacted quickly to the news. Shares climbed more than 3% following the announcement, reaching a fresh 52-week high.
By the latest trading session, the stock was changing hands at $8.74 — up 36% over the past week alone. Since the start of the year, shares have surged 349.24%, lifting ImmunityBio’s market capitalization to approximately $8.7 billion.
Building a Stronger European Presence
The new partnership clearly underscores ImmunityBio’s expanding ambitions in Europe. Management described the Accord Healthcare agreement as a pivotal move to unlock Anktiva’s commercial potential across the region.
To support this expansion, the company has established a new European subsidiary in Dublin, Ireland, to oversee distribution and commercialization efforts across the continent.
Chief Executive Officer Richard Adcock characterized the collaboration as a significant milestone in ImmunityBio’s European growth strategy. He noted that the partnership aligns with the company’s broader mission to reshape cancer care.
Under the agreement, Accord Healthcare will deploy more than 100 professionals across sales, medical, and marketing functions. These teams will focus on expanding Anktiva’s footprint across the European Union, the United Kingdom, Iceland, Norway, and Liechtenstein. Together, these steps create a coordinated framework for market entry and expansion.
Clinical Expansion and Regulatory Momentum
While commercial efforts accelerate, ImmunityBio (NASDAQ: IBRX) is also advancing its clinical objectives. Founder Patrick Soon-Shiong said the company aims to broaden patient access by completing a randomized trial in BCG-naïve patients. This group includes individuals with non-muscle invasive bladder cancer who have never received Bacillus Calmette-Guerin (BCG) therapy, as well as those whose disease recurred more than 24 months after prior BCG treatment.
Furthermore, regulatory developments are strengthening the company’s position. On Wednesday, the company announced that the European Union approved Anktiva for use in combination with BCG. This milestone strengthens ImmunityBio’s position in the bladder cancer treatment landscape and supports its broader European ambitions.
Similarly, momentum is also building in the Middle East. The Saudi Food and Drug Authority recently encouraged ImmunityBio to submit a regulatory filing for its recombinant BCG therapy. According to the company, the move aims to address treatment shortages and widen patient access.
In addition, the company confirmed ongoing discussions with Saudi regulators about expanding Anktiva’s use alongside checkpoint inhibitors across multiple tumor types. Notably, last month, Anktiva received accelerated approval from the SFDA for use in metastatic non-small cell lung cancer and BCG-unresponsive bladder cancer.
Taken together, these commercial partnerships and regulatory advancements signal a coordinated global expansion. ImmunityBio is steadily positioning Anktiva across new markets while strengthening its clinical and regulatory foundation.
Stay on top of healthcare stocks with our Healthcare Stock updates.
